Cargando…

The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)

In the past decade, the oncology community has witnessed major advances in the understanding of cancer biology and major breakthroughs in several different therapeutic areas, from solid tumors to hematological malignancies; moreover, the advent of effective immunotherapy approaches, such as immune-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Golan, Talia, Milella, Michele, Ackerstein, Aliza, Berger, Ranaan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745625/
https://www.ncbi.nlm.nih.gov/pubmed/29282151
http://dx.doi.org/10.1186/s13046-017-0668-0
_version_ 1783288938869293056
author Golan, Talia
Milella, Michele
Ackerstein, Aliza
Berger, Ranaan
author_facet Golan, Talia
Milella, Michele
Ackerstein, Aliza
Berger, Ranaan
author_sort Golan, Talia
collection PubMed
description In the past decade, the oncology community has witnessed major advances in the understanding of cancer biology and major breakthroughs in several different therapeutic areas, from solid tumors to hematological malignancies; moreover, the advent of effective immunotherapy approaches, such as immune-checkpoint blockade, is revolutionizing treatment algorithms in almost all oncology disease areas. As knowledge evolves and new weapons emerge in the “war against cancer”, clinical and translational research need to adapt to a rapidly changing environment to effectively translate novel concepts into sustainable and accessible therapeutic options for cancer patients. With this in mind, translational cancer researchers, oncology professionals, treatment experts, CRO and industry leaders, as well as patient representatives gathered in London, 16-17 March 2017, for The International Congress on Clinical Trials in Oncology and Hemato-Oncology (ICTO2017), to discuss the changing face of oncology clinical trials in the new era of personalized medicine and immuno-oncology. A wide range of topics, including clinical trial design in immuno-oncology, biomarker-oriented drug development paths, statistical design and endpoint selection, challenges in the design and conduct of personalized medicine clinical trials, risk-based monitoring, financing and reimbursement, as well as best operational practices, were discussed in an open, highly interactive format, favoring networking among all relevant stakeholders. The most relevant data, approaches and issues emerged and discussed during the conference are summarized in this report.
format Online
Article
Text
id pubmed-5745625
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57456252018-01-03 The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017) Golan, Talia Milella, Michele Ackerstein, Aliza Berger, Ranaan J Exp Clin Cancer Res Meeting Report In the past decade, the oncology community has witnessed major advances in the understanding of cancer biology and major breakthroughs in several different therapeutic areas, from solid tumors to hematological malignancies; moreover, the advent of effective immunotherapy approaches, such as immune-checkpoint blockade, is revolutionizing treatment algorithms in almost all oncology disease areas. As knowledge evolves and new weapons emerge in the “war against cancer”, clinical and translational research need to adapt to a rapidly changing environment to effectively translate novel concepts into sustainable and accessible therapeutic options for cancer patients. With this in mind, translational cancer researchers, oncology professionals, treatment experts, CRO and industry leaders, as well as patient representatives gathered in London, 16-17 March 2017, for The International Congress on Clinical Trials in Oncology and Hemato-Oncology (ICTO2017), to discuss the changing face of oncology clinical trials in the new era of personalized medicine and immuno-oncology. A wide range of topics, including clinical trial design in immuno-oncology, biomarker-oriented drug development paths, statistical design and endpoint selection, challenges in the design and conduct of personalized medicine clinical trials, risk-based monitoring, financing and reimbursement, as well as best operational practices, were discussed in an open, highly interactive format, favoring networking among all relevant stakeholders. The most relevant data, approaches and issues emerged and discussed during the conference are summarized in this report. BioMed Central 2017-12-28 /pmc/articles/PMC5745625/ /pubmed/29282151 http://dx.doi.org/10.1186/s13046-017-0668-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Meeting Report
Golan, Talia
Milella, Michele
Ackerstein, Aliza
Berger, Ranaan
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
title The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
title_full The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
title_fullStr The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
title_full_unstemmed The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
title_short The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
title_sort changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in oncology & hemato-oncology (icto 2017)
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745625/
https://www.ncbi.nlm.nih.gov/pubmed/29282151
http://dx.doi.org/10.1186/s13046-017-0668-0
work_keys_str_mv AT golantalia thechangingfaceofclinicaltrialsinthepersonalizedmedicineandimmunooncologyerareportfromtheinternationalcongressonclinicaltrialsinoncologyhematooncologyicto2017
AT milellamichele thechangingfaceofclinicaltrialsinthepersonalizedmedicineandimmunooncologyerareportfromtheinternationalcongressonclinicaltrialsinoncologyhematooncologyicto2017
AT ackersteinaliza thechangingfaceofclinicaltrialsinthepersonalizedmedicineandimmunooncologyerareportfromtheinternationalcongressonclinicaltrialsinoncologyhematooncologyicto2017
AT bergerranaan thechangingfaceofclinicaltrialsinthepersonalizedmedicineandimmunooncologyerareportfromtheinternationalcongressonclinicaltrialsinoncologyhematooncologyicto2017
AT golantalia changingfaceofclinicaltrialsinthepersonalizedmedicineandimmunooncologyerareportfromtheinternationalcongressonclinicaltrialsinoncologyhematooncologyicto2017
AT milellamichele changingfaceofclinicaltrialsinthepersonalizedmedicineandimmunooncologyerareportfromtheinternationalcongressonclinicaltrialsinoncologyhematooncologyicto2017
AT ackersteinaliza changingfaceofclinicaltrialsinthepersonalizedmedicineandimmunooncologyerareportfromtheinternationalcongressonclinicaltrialsinoncologyhematooncologyicto2017
AT bergerranaan changingfaceofclinicaltrialsinthepersonalizedmedicineandimmunooncologyerareportfromtheinternationalcongressonclinicaltrialsinoncologyhematooncologyicto2017